Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AbGn-107 in advanced GI cancers
NCT02908451Phase 1Terminated
- Sponsor
- AbGenomics
- Start
- Apr 2017
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of abgn-107 in gastric cancer (GC), colorectal cancer (CRC), pancreatic cancer (PC) and 1 more, sponsored by AbGenomics. Primary endpoint: Adverse events (AEs) graded according to CTCAE v4.03 at 28 days. Started Apr 2017; status: terminated.
02
Drugs
abgn-107
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)pancreatic cancer (PC)biliary cancer
Beyond the preview
Go deeper on NCT02908451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02908451.